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Abstract. Novel molecularly targeted agents (MTAs) have emerged as valuable alternatives
or complements to traditional cytotoxic agents in the treatment of cancer. Clinicians are com-
bining cytotoxic agents with MTAs in a single trial to achieve treatment synergism and better
patient outcomes. An important feature of such combinational trials is that, unlike the efficacy
of the cytotoxic agent, that of the MTA may initially increase at low dose levels and then ap-
proximately plateau at higher dose levels as MTA saturation levels are reached. Therefore, the
goal of the trial is to find the optimal dose combination that yields the highest efficacy with the
lowest toxicity and meanwhile satisfies a certain safety requirement. We propose a Bayesian
phase I/II design to find the optimal dose combination. We model toxicity using a logistic re-
gression and propose a novel proportional hazard model for efficacy, which accounts for the
plateau in the MTA dose-efficacy curve. We evaluate the operating characteristics of the pro-
posed design through simulation studies under various practical scenarios. The results show
that the proposed design performs well and selects the optimal dose combination with high
probability.
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21. Introduction
Traditional cytotoxic agents have played important roles in combating cancer. However,
after decades of research, it has become dicult to nd new cytotoxic agents that are sub-
stantially more eective than the existing therapeutic strategies. Recently, novel molecularly
targeted agents (MTAs), such as small molecules or monoclonal antibodies, have emerged
as alternatives or complements to cytotoxic agents for treating cancer (Le Tourneau et al.,
2010, 2011, 2012; Postel-Vinay et al., 2009). Unlike cytotoxic agents, MTAs modulate spe-
cic aberrant pathways in cancer cells, while sparing normal tissue. To take advantage of
both types of treatment agents, clinicians are exploring the possibility of combining tradi-
tional cytotoxic agents with novel MTAs to achieve treatment synergism and better patient
response.
This new trend of combining cytotoxic agents with MTAs for treating cancer brings new
challenges for early-phase dose-nding trial design. These challenges arise from the dier-
ence in the dose-ecacy curves between the two types of treatment agents. For cytotoxic
agents, more is better (i.e., a higher dose yields a greater response) until a dose-limiting
toxicity level is reached. However, the dose-ecacy relationship of the MTA may not follow
a monotonic pattern: the ecacy of the MTA often increases at low dose levels and then
plateaus (or approximately plateaus) at higher dose levels once a saturation level in the
body is reached (Le Tourneau et al., 2010; Hoering et al., 2011). Although it is possible
that ecacy decreases at higher dose levels, here we focus on the case in which ecacy
rst increases and then plateaus because such a dose-ecacy relationship is much more
commonly encountered in practice.
Consequently, the conventional dose-nding paradigm of searching for the maximum
tolerated dose (MTD) is not suitable for combinational trials of a cytotoxic agent with an
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MTA, and it is imperative to consider ecacy and toxicity simultaneously, with the goal
of nding the molecularly targeted optimal dose combination (ODC). This is because once
the MTA dose-ecacy curve reaches a plateau, further increases in the dose of the targeted
agent will not yield any therapeutic benet, but will potentially result in greater toxicity
(Postel-Vinay et al., 2009). In this article, the ODC is dened as the most ecacious dose
combination that yields the lowest toxicity. As the lowest toxicity can still be excessive, we
also require the ODC to satisfy a certain safety requirement, e.g., the toxicity probability
must be lower than a certain upper bound.
Numerous designs have been proposed to nd the MTD for trials combining multiple
cytotoxic agents, without considering the ecacy endpoint. For example, Thall et al. (2003)
developed a Bayesian approach to identify an entire toxicity \contour" of drug combina-
tions. Conaway et al. (2004) proposed a dose-nding method based on the simple and
partial orders of drug combinations. Yuan and Yin (2008) proposed a sequential dose-
nding design that allows single-agent dose-nding methods to be used in multiple-agent
combination trials. Braun and Wang (2010) proposed a hierarchical-model-based approach
for dose nding. Yin and Yuan (2009) developed a Bayesian dose-nding method based on
a copula-type regression model. Wages et al. (2011) extended the continual reassessment
method to two-dimensional dose nding. Recently, several phase I/II drug-combination
trial designs have been proposed to account for both toxicity and ecacy. Focusing on a
combination of cytotoxic agents, Huang et al. (2007) proposed a phase I/II design based on
the \3+3" type dose escalation scheme, and Yuan and Yin (2011) developed a model-based
approach to accommodate toxicity and ecacy for combination trials. Mandrekar et al.
(2007) proposed a dose-nding design for trials combining two MTAs based on a continua-
tion ratio model for trinary outcomes. Cai and Ji (2014) proposed a Bayesian dose-nding
4design for trials combining two MTAs, which used a change point model to reect that
the dose-toxicity surface of combinations may plateau. Despite this rich body of literature,
no design is available for clinical trials combining a cytotoxic agent with an MTA, which
requires simultaneously accounting for the dierent behaviors of the cytotoxic agent and
the MTA. In addition, the existing phase I/II drug-combination designs assume that the
ecacy outcome is immediately ascertainable; however, this assumption may not hold in
many practical situations because, unlike the toxicity endpoint, the ecacy endpoint often
requires a relatively long time to assess.
We propose a Bayesian phase I/II design to nd the ODC for trials combining a cytotoxic
agent with an MTA. We model ecacy as a time-to-event outcome rather than a binary
outcome, thereby eliminating the requirement that the ecacy outcomes of treated patients
must be fully evaluated before a new cohort can be enrolled into the trial. To account for
the feature of the MTA whereby the dose-ecacy curve may initially increase and then
plateau, we incorporate a plateau parameter into the proportional hazard model for time
to ecacy. We model the binary toxicity outcome using a logistic regression model. During
the trial, we continuously updated the model estimates and use them to assign patients to
the ODC.
The remainder of the article is organized as follows. In Section 2, we present a case
study that has motivated the proposed methodology. In Section 3, we propose toxicity and
ecacy models, and describe a dose-nding algorithm to identify the ODC. In Section 4, we
present simulation studies to evaluate the operating characteristics of the proposed design
and investigate its sensitivity to model specications. We conclude with a brief discussion
in Section 5.
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2. A solid tumor clinical trial
Pishvaian et al. (2012) reported a phase I dose-nding clinical trial for the combination
of imatinib and paclitaxel in patients with advanced solid tumors refractory to standard
therapy. Imatinib is a tyrosine-kinase inhibitor used in the treatment of multiple cancers,
most notably chronic myelogenous leukemia (CML). Imatinib works by inhibiting the ac-
tivity of the BCR-Abl tyrosine kinase enzyme that is necessary for cancer development,
thus preventing the growth of cancer cells and leading to their death by apoptosis. Because
the BCR-Abl tyrosine kinase enzyme exists only in cancer cells and not in healthy cells,
imatinib works eectively as an MTA killing only cancer cells through its action. The goal
of the trial was to evaluate the safety of combining imatinib with the traditional cytotoxic
chemotherapeutic agent paclitaxel, and to determine whether that combination improved
the ecacy of imatinib. In the trial, four doses (300, 400, 600, 800 mg) of imatinib and three
doses (60, 80, 100 mg/m2) of paclitaxel were investigated. Most of the grade 3 or 4 toxic-
ities related to therapy involved neutropenia, u-like symptoms, and pain. The treatment
response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST).
This phase I trial adopted the conventional \3+3" design, which unfortunately suers
from several limitations. First, as the \3+3" design requires that the doses under investi-
gation must be monotonically increasing, only a subset of all 12 possible combinations of
imatinib and paclitaxel were investigated in the trial. As a result, the trial might not have
even examined the most desirable dose in the 4  3 dose combination space. Specically,
the trial selectively investigated 6 dose combinations: (paclitaxel, imatinib) = (60, 300),
(60, 400), (80, 400), (80, 600), (100, 600) and (100, 800). The original protocol involved an
intensive dose schedule, with continuous daily oral administration of imatinib and weekly
paclitaxel infusions. However, after treating patients at the rst two doses, the regimen
6resulted in an excessive number of adverse events, and thus the protocol was amended to a
less intensive schedule, with intermittent dosing of imatinib. The second limitation of this
use of the \3+3" design is that it ignores the important fact that the ecacy of imatinib
does not monotonically increase with the dose, and that the MTD may not be the optimal
dose for treating patients. Druker (2002) pointed out that, for treating CML, a dose of 400
to 600 mg of imatinib reached the plateau of the dose-response curve. As a result, 400 mg
or 600 mg is the dose of imatinib that is commonly used in clinical practice. This result was
conrmed in a meta-analysis (Gafter-Gvili et al., 2011) of phase III randomized trials, in
which no treatment dierence was found between 400 mg and higher doses of imatinib. This
trial example demonstrates the need for a new dose-nding design to handle the clinical
trials that combine an MTA with a traditional cytotoxic agent. We apply our design to the
trial in Section 4.
3. Methods
3.1. Toxicity model
Consider a trial combining J doses of cytotoxic agent A withK doses of molecularly targeted
agent (MTA) B, and denote (j; k) as the combination of the jth dose level of agent A with
the kth dose level of agent B. We assume that toxicity (i.e., the dose-limiting toxicity
dened by the trial investigator) is quickly ascertainable and monotonically increases with
the doses of both agents A and B; this assumption generally holds for cytotoxic agents and
is plausible for most MTAs.
Let yi denote the binary toxicity outcome of patient i with yi = 1 indicating a toxicity
response, and pjk denote the toxicity probability of combination (j; k) for j = 1; : : : ; J and
k = 1; : : : ;K. We model toxicity using a logistic model as follows,
logit(pjk) = 0 + 1uj + 2vk (1)
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where 0, 1, and 2 are unknown parameters, and uj and vk are \eective" doses ascribed
to the jth dose level of agent A and the kth dose level of agent B based on the prior
estimates of the single-agent toxicity probabilities for these two dose levels. The procedure
of determining the values of uj and vk will be described in Section 3.4. We require 1 > 0
and 2 > 0 so that toxicity monotonically increases with the dose levels of both agents A
and B.
Assuming that during the trial conduct, among the njk patients administered the com-
bination (j; k), mjk patients experienced toxicity, then the likelihood of the toxicity data
Dtox = fnjk;mjkg is
L(Dtoxj0; 1; 2) /
JY
j=1
KY
k=1
p
mjk
jk (1  pjk)njk mjk :
Letting (0; 1; 2) denote the prior distribution of 0; 1 and 2, the posterior is then
given by
f(0; 1; 2jDtox) / (0; 1; 2)L(Dtoxj0; 1; 2): (2)
In model (1), we do not include an interactive eect of the two agents (e.g., an interaction
term 3ujvk) because the reliable estimation of such an interaction term requires a large
sample size (e.g., a few hundred), which is typically not available in early-phase trials. Our
numerical study suggests that including the interaction term does not improve but often
impairs the performance of the design (results are not shown). Note that for the purpose
of dose nding, our goal is not to accurately model the entire dose-toxicity surface, but to
obtain an adequate local t to facilitate dose escalation and de-escalation. A model may
provide a poor global t for the entire dose-toxicity surface; however as long as the model
provides a good local t around the current combination, it will lead to correct decisions of
dose escalation and dose selection (O'Quigley and Paoletti, 2003).
83.2. Efficacy model
Unlike toxicity, which often can be observed quickly, the ecacy response may require a
relatively long follow-up time to be scored. In this circumstance, the conventional approach
of treating ecacy as a binary outcome causes a serious logistic issue: when a new patient
is enrolled and is waiting for dose assignment, some of patients already treated in the trial
might not have nished their evaluation yet, and thus their response outcomes are not
available to make the decision of dose assignment for the new patient. To overcome this
diculty, we herein model the response as a time-to-event outcome, in which the data of
the incomplete ecacy evaluations are naturally incorporated into the decision making of
dose assignment as censored observations.
Let t denote the time to response. In early phase clinical trials, the typical way to
evaluate ecacy is to follow each patient for a xed period of time T , e.g., 3 months, after
the initiation of the treatment. Within the assessment window (0, T], if the patient responds
favorably to the treatment (i.e., t  T ), it is scored as a response, otherwise nonresponse.
The ecacy of the drug is dened as the response rate at T . Patient's outcomes after T
will not be used to dene the ecacy of the drug and make the decision of dose escalation
and selection. In other words, the time to response t is always administratively censored
at T . Although we cannot observe any t beyond the time point T , it does not cause any
issue here because for the purpose of evaluating the ecacy of the drug and nding the
optimal dose, by denition, we only concern the response rate at T , i.e., 1   S(T ), where
S() denotes the survival function of t. For the same reason, conceptually, we can regard
t = 1 for the patients who do not benet from the treatment without aecting the dose
nding. A special feature of the trial combining an MTA with a cytotoxic agent is that the
dose-ecacy curve behaves dierently with respect to the two agents: ecacy is expected
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to monotonically increase with the dose of the cytotoxic agent, but not with the dose of the
MTA. Ecacy often initially increases and then plateaus with the dose of the MTA after the
MTA reaches a level of saturation. Let jk(t) denote the hazard function associated with
combination (j; k), and 1(C) denote the indicator function, which takes a value of 1 if C is
true. We model the time to ecacy for the combination of an MTA and a cytotoxic agent
using a proportional hazard model, augmented with a plateau parameter  , as follows,
jk(t) = 0(t)expf1wj + 2(zk1(k < ) + z1(k  ))g;
where 0(t) is the baseline hazard, and wj and zk are \eective" doses ascribed to the jth
dose level of agent A and the kth dose level of agent B based on the prior estimates of the
single-agent ecacy probabilities for these two doses, which will be described in the next
section. We assume that 1 > 0 and 2 > 0, and therefore ecacy monotonically increases
with the dose of the cytotoxic agent A (i.e., wj). The plateau parameter  is an integer
between 1 andK and indicates at which dose level of agent B (i.e., the MTA) ecacy reaches
a plateau. When the dose level is lower than  , the ecacy monotonically increases with the
dose of the MTA (i.e., zk) through the covariate eect 2(zk1(k < )+ z1(k  )) = 2zk;
and when the dose level is equal to or higher than  , the ecacy plateaus (with respective
to the dose level of agent B) with a constant dose eect 2z .
Due to the small sample size of early-phase trials, we take a parameter approach and
assume an exponential distribution for the time to ecacy with a constant baseline hazard,
i.e., 0(t) = 0, resulting in the following survival function for the time to ecacy
Sjk(t) = exp[ 0t expf1wj + 2(zk1(k < ) + z1(k  ))g]:
Then, the response rate at the end of T for patients treated at the combination (j; k),
denoted by qjk, is given by qij = 1 Sjk(T ). In our design, qjk will be used as the measure
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of ecacy for determining the dose transition and selection.
For patient i, let si denote the actual follow-up time, ti denote the time to response,
and (ji; ki) denote the combination administered to the patient. Dene xi = min(T; si; ti)
and censoring indicator i = 1(xi = ti). Given the ecacy data De = fxi; ig obtained
from n patients, the likelihood is given by
L(De j0; 1; 2; ) /
nY
i=1
ijiki(xi)Sjiki(xi);
and the posterior is
f(0; 1; 2;  jDe) / (0; 1; 2; )L(De j0; 1; 2; ); (3)
where (0; 1; 2; ) is the prior for the unknown parameters.
3.3. Specification of prior and effective doses
We rst discuss the specication of priors for the model parameters. For the toxicity
model, we adopted a vague normal prior N(0; 100) for the intercept 0, and, following
Chevret (1993), we assigned the slopes 1 and 2 independent exponential distributions
with a rate parameter of 1, i.e., 1; 2  Exp(1). For the ecacy model, we took vague
priors 0  Exp(0:01) and 1, 2  Exp(0:1), and assigned  a multinomial distribution
with probability parameters  = (1; :::; K), where k is the prior probability that the
dose-ecacy curve plateaus at dose level k of the MTA. When there is rich information on
the location of  , e.g., we know the saturation dosage of the MTA from pharmacokinetic
and pharmacodynamic studies, we can choose a set of  to reect the likelihood of each
dose level being the plateau point. When there is no good prior information regarding the
location of  , we recommend assigning  an increasing sequence of prior probabilities (i.e.,
1 < 2 < ::: < K) rather than a noninformative at prior 1 = 2 = ::: = K . This
recommendation is based on our experience with numerical studies, in which we found that
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using a noninformative prior often caused the dose selection to remain at low dose levels due
to the sparsity of data; whereas the prior with increasing k's encourages the dose-nding
algorithm to explore higher dose levels of agent B and actively learn the shape of the dose-
ecacy curve, thereby improving the ODC selection accuracy. In our simulation study, we
took  = (0:14; 0:20; 0:28; 0:39), which led to good operating characteristics across various
scenarios. A summary of prior distributions is given in Table 1. After specifying the prior
distributions, we sampled posterior distributions (2) and (3) using the Gibbs sampler.
We next discuss how to specify the eective doses (i.e., uj 's and vk's in the toxicity
model, and wj 's and zk's in the ecacy model) based on the prior estimates of the single-
agent toxicity and ecacy probabilities. In practice, before two agents are to be combined,
each of them typically has been studied individually. For example, prior to the solid tumor
clinical trial that combines imatinib with paclitaxel (Pishvaian et al., 2012), many phase I
and II trials have been conducted to study the single-agent toxicity and ecacy proles for
imatinib (Ramanathan et al., 2008; Gibbons et al., 2008; Lipton et al., 2010; van Oosterom
et al., 2001) and paclitaxel (Kato et al., 2011; Tsimberidou et al., 2011; Takano et al., 2002;
Lim et al., 2010; Horiguchi et al., 2009). Therefore, we often have good prior estimates of the
single-agent toxicity and ecacy probabilities for each of the agents. The purpose of dening
and using the eective doses is to match the prior estimates of (single-agent) toxicity and
ecacy probabilities under our model with those elicited from the prior information. By
doing so, we incorporate the available single-agent dose-toxicity and -ecacy information
into our model and thus improve the eciency of the design. This approach has been
previously used for dose nding in single-agent trials (Chevret, 2006; Zohar et al., 2013)
and drug-combination trials (Liu and Ning, 2013).
Specically, let p^j0 and p^0k denote the estimates of the single-agent toxicity probabilities
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for the jth level of agent A and the kth level of agent B, respectively, and q^j0  1  S^j0(T )
and q^0k  1  S^0k(T ) denote the estimates of the single-agent ecacy probabilities for the
jth level of agent A and the kth level of agent B (at the end of follow-up). Under toxicity
model (1), by setting the dosage of agent B (or A) as zero, we obtain the single-agent
toxicity model logit(pj0) = 0 + 1uj for agent A and logit(p0k) = 0 + 2vk for agent B.
Therefore, based on the prior estimates p^j0 and p^0k , we backsolve the eective doses uj
and vk as
uj = flogit(p^j0)  ^0g=^1
vk = flogit(p^0k)  ^0g=^2;
where ^0 and ^1 are prior means of 0 and 1. Similarly, under ecacy survival model
(2), the single-agent ecacy model is Sj0(t) = expf 0:t:exp(1wj)g for agent A and
S0k(t) = exp[ 0:t:expf2(zk1(k < ) + z1(k  ))g] for agent B. We determine the
eective doses
wj = log[ logf1  q^j0g=(^0T )]=^1
zk = log[ logf1  q^0kg=(^0T )]=^2;
where ^0; ^1; ^2 are prior estimates of the corresponding parameters, and ^ is the highest
dose levels.
3.4. Dose-finding algorithm
At the beginning of the trial, data are very sparse and the estimates of the toxicity and
ecacy models are highly unreliable. To improve the reliability of dose nding, we use a
start-up phase to collect some preliminary data prior to switching to the formal model-based
dose-nding algorithm.
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We adopted a start-up phase similar to that proposed by Huang et al. (2007), which
divides the dose combination matrix into a sequence of zones along the diagonal from low
doses to high doses (see Figure 1), and then conducts a \3+3" type dose escalation across the
zones. Specically, we initiate the start-up phase by treating the rst cohort of 3 patients at
the lowest zone, i.e., the lowest combination (1; 1), and then continuously escalate the dose
to higher dose zones until we rst encounter a zone in which all doses are \closed." Given
a dose, if more than 1 patient were to experience toxicity out of the 3 or 6 patients who
have been administered that dose, we close the dose and require that all higher doses (i.e.,
any combination having a higher dose level of A or B or A and B) are automatically closed
and not eligible for use in treating future patients in the start-up phase. More precisely, if
we close dose combination (j; k), we also close higher doses f(j0; k0); j0  j and k0  kg.
The \closed" dose combinations can be reopened later to treat patients in the subsequent
model-based dose-nding phase if the accumulating data indicate that they are actually
safe. The dose escalation across zones is analogous to the traditional \3+3" dose escalation
rule: among three patients, if we observe no toxicity, we escalate the dose; if more than 2
patients experience toxicity, we close the dose; and if 1 patient experiences toxicity, we treat
three more patients at the current dose. In the latter case, if 0 or 1 out of the 6 patients
experiences toxicity, we escalate the dose; otherwise we close the dose. When we escalate
to a higher dose zone, if there are multiple combinations that are not closed in that zone,
we simultaneously assign patients to each of the combinations.
After the start-up phase, we switch to the model-based dose-nding phase. Let  and 
denote the prespecied toxicity upper bound and ecacy lower bound, respectively. Let N
denote the total sample size, and n denote the number of patients treated in the trial. We
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dene that a combination (j; k) is admissible if it satises the safety requirement
P (pjk > ) < CT (4)
and also the ecacy requirement
P (Sjk(T ) > )  CE1(n  N=2); (5)
where CT and CE are the respective probability thresholds for toxicity and ecacy. Note
that the ecacy requirement (5) takes eect when only half of the patients have been
enrolled, as controlled by the indicator function 1(n  N=2). We found that introducing
the ecacy condition too early caused a high frequency of misclassication of the admissible
doses as inadmissible and thus resulted in the early termination of the trial. This situation
can arise because, compared to the evaluation of the toxicity condition (4), the reliable
evaluation of the ecacy condition (5) requires more data, as the ecacy outcome is not
immediately observable and the ecacy model is relatively more complicated.
Let (j; k) denote the current dose, A denote the set of combinations that have been
previously used to treat patients, and B = f(j0; k0); j0  j + 1; k0  k + 1; and (j0; k0) 6=
(j+1; k+1)g denote the set of combinations for which the doses are not two levels higher than
the current dose (j; k). Our model-based dose-nding algorithm can be described as follows:
after the start-up phase, we assign the next cohort of patients to the optimal combination
that is admissible and which also has the highest estimate of ecacy, i.e., 1  S^(T ), selected
from the set A[B. If several such optimal combinations exist, e.g., the ecacy has reached
a plateau with respect to the dose level of the MTA, we select the one with the lowest
toxicity probability (e.g., the optimal combination with the lowest MTA dose level) to treat
the new cohort. At any time, if all combinations are not admissible, then we terminate the
trial; otherwise, we continue this dose assignment process until the maximum sample size
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is reached. At the end of the trial, we select the ODC as the admissible combination that
has the highest estimate of ecacy along with the lowest estimate of toxicity.
4. Numerical Studies
4.1. Simulation study
We carried out extensive simulations to evaluate the operating characteristics of the pro-
posed phase I/II design. Taking the setting of the aforementioned solid tumor trial, we
assumed 3 dose levels for cytotoxic agent A (i.e., paclitaxel) and 4 dose levels for molec-
ularly targeted agent B (i.e., imatinib), resulting in a total of 12 combinations. We took
the initial guesses of the single-agent toxicity and ecacy as (0:2; 0:3; 0:4) and (0:3; 0:4; 0:5),
respectively, for agent A, and (0:12; 0:2; 0:3; 0:4) and (0:3; 0:4; 0:5; 0:59) for agent B. The
maximum sample size was 75 and patients were treated sequentially in cohorts of size 3.
We assumed that the patient accrual followed a Poisson process with the rate of 1=3:5
patients per week. The toxicity upper bound was  = 0:30 and the ecacy lower bound
was  = 0:20. We set the toxicity threshold as CT = 0:85 and the ecacy threshold as
CE = 0:10, and took the prior probabilities of the dose-ecacy curve reaching a plateau
at the dierent dose levels of agent B as (0:16; 0:21; 0:27; 0:36). We considered 8 dierent
dose-toxicity and ecacy scenarios (see Table 2), representing what we may encounter in
practice. We assumed that toxicity was quickly evaluable, while the evaluation of ecacy
required 7 weeks, i.e., T = 7 weeks. Under each scenario, we assumed that at each com-
bination, the time to ecacy followed an exponential distribution. The parameter of the
exponential distribution was chosen such that at the end of follow-up, the ecacy rate of
each dose combination (i.e., 1 Sjk(T )) matched those displayed in Table 2. As a result, the
parameter of the exponential distribution had to vary across doses. Under each scenario,
we conducted 1,000 simulations.
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Table 3 shows the simulation results, including the ODC selection percentage, the av-
erage number of patients assigned to the ODC, and the average number of dose-limiting
toxicities (DLTs). We also reported the \eective dose combination" (EDC) selection per-
centage, dening the EDCs as the admissible combinations that yield the same (highest)
ecacy as the ODC and which also have acceptable toxicity, i.e., the toxicity probability of
the EDC is not necessarily the lowest among several equally ecacious combinations. For
example, in scenario 2 in Table 2, both (3, 1) and (3, 2) have the same high ecacy rate of
55% and acceptable toxicity rates not higher than 30%. The ODC is (3, 1) as it has a lower
toxicity probability or lower MTA dose level (i.e., agent B); whereas both (3, 1) and (3, 2)
are EDCs as they are both safe and ecacious. Although the ODC is optimal, in practice,
the EDCs are also of interest due to their high ecacy even though their dose of agent B
may be higher than what is actually needed. Note that under our denitions, the ODC is
one of the EDCs, but not vice versa. Table 4 provides more detailed simulation results for
the selection percentages and the number of patients treated at each dose combination.
In general, the proposed design performed well across 8 scenarios. The ODC and EDC
selection percentages were generally greater than 50%, and the design allocated a large
number of patients to the ODC and EDCs. Specically, in scenario 1, the dose-ecacy
curve (approximately) plateaus at the lowest dose level of the targeted agent B, and the
ODC is the combination (3; 1), which yields the highest ecacy with the lowest dose of
the targeted agent. This ODC is also the only EDC in scenario 1. To mimic what may
happen in practice, we designed the scenarios to allow for some variation in ecacy, even
when it has reached the plateau. The proposed design selected the ODC 75.6% of the time,
and allocated on average 35.1 patients to the ODC. As in scenario 1, in scenario 2, the
dose-ecacy curve plateaued from the lowest dose level of the targeted agent B with (3; 1)
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as the ODC, but with two EDCs, i.e., (3; 1) and (3; 2). Note that combinations (3; 3) and
(3; 4) have high ecacy probabilities that are similar to that of the ODC (3; 1), but they
are not EDCs because they are not admissible combinations due to high toxicity. In this
case, the proposed design selected the ODC and EDCs 62.0% and 94.0% of the time. In
scenario 3, the dose-ecacy curve plateaus after dose level 1 of agent B. The ODC and
EDC selection percentages in that scenario were 51.3% and 96.9%, respectively. Scenarios 4
and 5 both have ecacy plateaus after dose level 2 of agent B, but with dierent locations
for the ODC and EDCs. In these two cases, the ODC selection percentages were more than
40%. Scenarios 6 to 8 simulate ecacy monotonically increasing with the dose of agent B
(e.g., agent B does not reach a level of saturation within the range of the investigational
doses), with dierent numbers for the ODCs, which is similar to what may happen in
conventional combination trials with two cytotoxic agents. The simulations demonstrate
that our proposed design performed well and achieved ODC and EDC selection percentages
that were all higher than 60%, suggesting that the proposed design can also be applied to
the combination of two cytotoxic agents.
4.2. Sensitivity analysis
We performed sensitivity analyses to study the robustness of our design. We varied four fac-
tors: (1) the prior estimates of the single-agent toxicity and ecacy probabilities; (2) the dis-
tribution of time to ecacy; (3) the variance of the prior distribution for 0; 1; 2; 0; 1; and2;
and (4) the prior distribution for  . We assumed that the single-agent toxicity and ef-
cacy probabilities, used to determine the \eective" dose in the toxicity and ecacy
model, were (0:06; 0:12; 0:2) and (0:12; 0:2; 0:3) for agent A, and (0:06; 0:12; 0:2; 0:3) and
(0:4; 0:5; 0:59; 0:67) for agent B. We simulated the time to ecacy from a Weibull distribu-
tion with a xed shape parameter of 3. We chose the scale parameter of the Weibull distribu-
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tion such that the ecacy probabilities at the end of follow-up, i.e., 1 S(T ), matched those
given in Table 2. We inated the prior variances of parameters 0; 1; 2; 0; 1; and 2 by
2-fold, and used  = (0:11; 0:17; 0:28; 0:44) as the prior probabilities of  . Table 5 shows
the results of the sensitivity analyses. We can see that the ODC and EDC selection per-
centages and the number of patients treated at the ODC and EDCs are generally similar to
those reported in Table 3, which suggests that the proposed design is not sensitive to the
aforementioned design factors.
4.3. Application
We retrospectively applied our design to the solid tumor trial. As described previously,
the trial selectively studied six dose combinations out of 12 possible combinations. Because
the dosing schedule used in the original protocol resulted in too many toxicities, the protocol
was amended to use a less intensive dose schedule. As a result, ve dose combinations were
actually used for dose nding under the amended schedule, as shown in Table 6. The window
for assessing treatment response was set at T = 13 weeks. The trial did not report the time
to response; thus, we assumed that it was uniformly distributed within the assessment
window. To be consistent with the \3+3" method used by the trial, we set CT = 0:33 and
CE = 0:0, and forbade skipping untried doses during the dose escalation.
The trial started by treating the rst cohort of 3 patients at the lowest dose combination
(60, 400), at which one response and no dose-limiting toxicity (DLT) was observed. Based
on the data, our method identied dose combination (100, 600) as the ODC, with an
estimated response rate of 0.54, and thus recommended dose escalation to (80, 400) for
treating the second cohort of patients. Among the three patients treated at (80, 400), two
responded to the treatment and no DLT was observed. In light of this new information,
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our method estimated combination (100, 600) as the ODC, with an estimated response rate
of 0.56. Accordingly, we escalated the dose to (80, 600) for treating the third cohort of 3
patients, among which 2 patients responded to the treatment and no DLT was observed.
Our method then escalated the dose and assigned the fourth cohort to dose combination
(100, 600), at which we observed 2 responses and no DLT. At that moment, the estimated
ODC was dose combination (100, 600), with the estimated response rate of 0.45. Based on
this result, our method would retain the current dose and assign the remaining 6 patients
to (100, 600); whereas the \3+3" design dictated a dose escalation to (100, 800). At the
end of the trial, our design selected (100, 600) as the ODC, while the \3+3" design picked
(100, 800). According to the literature, a dose of 600mg of imatinib reaches the plateau of
the dose-response curve and actually is the dosage that has been widely administered to
cancer patients in practice. It seems that our design successfully identied that, while the
\3+3" design might have resulted in overdosing of patients by selecting a dose of 800mg.
5. Conclusions
We have proposed a Bayesian phase I/II design for trials that combine a cytotoxic agent
with a molecularly targeted agent. We assumed that toxicity is quickly evaluable and
used a logistic regression model to evaluate toxicity as a binary outcome. In contrast, we
assumed that ecacy takes a relatively long time to evaluate, and correspondingly used a
proportional hazard model to evaluate ecacy as a time-to-event outcome. To account for
the characteristic dose-ecacy curve for MTAs, which initially increases and then plateaus,
we incorporated a plateau point into the time-to-ecacy model. During the trial conduct,
we continuously updated the model estimates and used them to assign patients to the ODC.
We evaluated our design through a simulation study under various practical scenarios. Our
design performed well by selecting the optimal dose combination a high percentage of the
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time.
The proposed design assumes that the treatment response can be observed anytime
during the followup period. For some clinical trials, the response however can only be
ascertained at the end of followup, for example, when the response is dened as a certain
percentage of tumor shrinkage at time T . In these cases, rather than modeling the time to
response, we can model the time to disease progression (i.e., time to nonresponse), which
typically is observable in real time based on patient's symptoms. The proposed model and
design can still be used. We just need to treat t as the time to nonresponse, and accordingly
estimate the response rate qjk at T by Sjk(T ), rather than 1  Sjk(T ).
There are several possible extensions of the proposed design to further improve its per-
formance or exibility in order to accommodate dierent clinical applications. For example,
rather than modeling toxicity as a binary outcome, we can use measurements of the various
grades of toxicity and model it as an ordinary outcome. This approach uses more rened
information and can potentially improve the eciency of the trial design. In addition, when
late-onset toxicity is of concern, we can model toxicity as a time-to-event outcome, as we
have done for ecacy. Lastly, our dose assignment and selection criteria focus on ecacy
while controlling for toxicity. In some applications, it may be more appropriate to consider
the tradeo between toxicity and ecacy. To accommodate these cases, we can dene a
utility function for the tradeo between toxicity and ecacy and then use the utility as the
criterion for dose assignment and selection.
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Table 1. Prior distributions for model parameters.
Parameter Prior distribution
0 N(0; 100)
1, 2 Exp(1)
0 Exp(0:01)
1, 2 Exp(0:1)
 Multinomial(1; :::; K) with 1 < ::: < K
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Table 2. Eight toxicity and efficacy scenarios for the combination of a cytotoxic agent (agent A) with a
molecularly targeted agent (agent B). The optimal dose combinations (ODCs) are in bold and the effective
dose combinations (EDCs) are underlined. The dashed lines indicate the dose level of the MTA at which the
efficacy plateaus.
Agent A Agent A
Agent 1 2 3 1 2 3 1 2 3 1 2 3
B Toxicity Ecacy Toxicity Ecacy
Scenario 1 Scenario 2
4 0.45 0.50 0.65 0.27 0.42 0.56 0.30 0.45 0.55 0.28 0.43 0.57
3 0.30 0.45 0.55 0.26 0.41 0.56 0.15 0.30 0.45 0.27 0.42 0.56
2 0.15 0.30 0.45 0.25 0.41 0.55 0.12 0.15 0.30 0.26 0.40 0.55
1 0.10 0.15 0.30 0.25 0.40 0.55 0.08 0.10 0.15 0.25 0.40 0.55
Scenario 3 Scenario 4
4 0.10 0.15 0.30 0.37 0.52 0.67 0.10 0.15 0.30 0.32 0.46 0.61
3 0.07 0.10 0.15 0.36 0.51 0.66 0.08 0.10 0.15 0.30 0.45 0.60
2 0.05 0.08 0.10 0.35 0.50 0.65 0.04 0.05 0.10 0.20 0.30 0.40
1 0.01 0.05 0.07 0.15 0.25 0.35 0.01 0.03 0.07 0.05 0.10 0.20
Scenario 5 Scenario 6
4 0.30 0.55 0.65 0.41 0.56 0.67 0.10 0.15 0.30 0.40 0.55 0.70
3 0.15 0.45 0.55 0.40 0.55 0.65 0.07 0.10 0.15 0.25 0.40 0.55
2 0.10 0.30 0.45 0.15 0.20 0.25 0.05 0.08 0.10 0.15 0.30 0.40
1 0.05 0.15 0.30 0.05 0.10 0.15 0.01 0.05 0.07 0.05 0.10 0.30
Scenario 7 Scenario 8
4 0.50 0.60 0.65 0.50 0.60 0.70 0.45 0.55 0.65 0.50 0.60 0.70
3 0.45 0.55 0.60 0.45 0.50 0.60 0.30 0.45 0.60 0.45 0.52 0.63
2 0.30 0.45 0.50 0.30 0.45 0.50 0.15 0.30 0.50 0.30 0.45 0.50
1 0.15 0.30 0.45 0.15 0.30 0.45 0.10 0.15 0.30 0.20 0.30 0.45
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Table 3. Selection percentage of the optimal dose combination (ODC) and effective dose combination (EDC),
the average number of patients treated at the ODC and EDC, and the average number of dose-limiting toxicities
(DLTs).
Scenarios
1 2 3 4 5 6 7 8
ODC selection percentage 75.6 62.0 51.3 51.3 42.1 66.4 62.8 78.3
Mean number of patients at ODC 35.1 25.1 17.4 18.1 14.4 23.1 32.5 40.9
Mean number of DLTs 22.5 16.7 9.4 10.8 21.9 12.0 25.8 23.7
EDC selection percentage 75.6 94.0 96.9 83.8 68.1 66.4 62.8 78.3
Mean number of patients at EDC 35.1 43.9 42.2 34.4 28.8 23.1 32.5 40.9
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Table 4. ODC (in boldface) and EDC (underlined) selection percentages and the average number of
patients treated at each combination.
Selection percentage Average number of patients
Scenario 1 Scenario 2 Scenario 1 Scenario 2
0.4 0.1 0.1 0.2 0.2 0.0 2.0 0.2 0.2 3.0 0.9 1.2
0.9 1.0 0.0 0.1 1.0 3.6 4.0 1.3 1.3 3.4 2.7 5.2
0.5 7.4 6.0 0.0 0.8 32.0 3.9 5.8 10.3 3.6 3.5 18.8
0.1 7.9 75.6 0.0 0.0 62.0 4.0 6.9 35.1 3.7 3.8 25.1
Scenario 3 Scenario 4 Scenario 3 Scenario 4
0.0 0.0 16.7 0.0 0.8 32.5 3.5 2.9 10.3 3.5 3.3 16.3
0.0 0.0 28.9 0.0 0.1 51.3 3.4 3.3 14.5 3.6 3.4 18.1
0.0 0.0 51.3 0.0 0.0 13.9 3.3 3.5 17.4 3.4 3.3 9.4
0.0 0.0 3.1 0.0 0.0 1.4 3.1 3.4 6.5 3.1 3.2 4.5
Scenario 5 Scenario 6 Scenario 5 Scenario 6
26.0 0.8 0.0 0.0 1.2 66.4 14.4 3.3 0.9 3.4 3.2 23.1
42.1 16.5 1.3 0.0 0.0 19.8 14.4 10.0 2.6 3.5 3.2 13.1
0.1 2.9 3.9 0.0 0.0 9.1 4.4 5.5 5.1 3.4 3.4 7.1
0.0 0.1 5.1 0.0 0.0 3.5 3.4 4.2 6.6 3.1 3.4 5.1
Scenario 7 Scenario 8 Scenario 7 Scenario 8
1.8 0.0 0.0 4.8 0.3 0.0 2.6 0.2 0.1 4.8 0.7 0.3
8.0 0.1 0.0 16.3 3.1 0.0 7.8 0.7 0.3 9.4 3.3 1.4
27.7 3.6 1.1 3.4 19.5 7.2 14.9 4.1 2.3 5.3 9.5 8.6
2.7 35.1 13.0 0.0 2.8 42.5 7.1 17.6 14.9 3.8 5.7 22.0
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Table 5. Results of the sensitivity analysis.
Scenarios
1 2 3 4 5 6 7 8
Dierent prior estimates for single agents
ODC selection percentage 74.7 63.4 50.6 56.9 44.2 65.4 62.2 79.7
Mean number of patients at ODC 74.7 93.6 96.4 85.0 70.0 65.4 62.2 79.7
Mean number of DLTs 0.4 0.0 0.0 0.0 1.8 0.0 7.4 0.3
EDC selection percentage 34.8 25.6 17.1 19.1 15.0 23.0 33.9 41.8
Mean number of patients at EDC 34.8 43.9 41.9 34.4 29.8 23.0 33.9 41.8
Time to ecacy following a Weibull distribution
ODC selection percentage 78.3 72.0 64.0 47.1 38.1 49.4 64.1 78.5
Mean number of patients at ODC 78.3 96.2 92.6 65.0 56.5 49.4 64.1 78.5
Mean number of DLTs 0.4 0.2 0.0 0.0 0.0 0.0 2.3 0.2
EDC selection percentage 35.7 27.7 20.2 17.3 12.8 16.9 32.8 41.0
Mean number of patients at EDC 35.7 45.2 40.4 29.0 23.5 16.9 32.8 41.0
Double the prior variances of (0; 1; 2; 0; 1; 2)
ODC selection percentage 70.5 46.3 45.9 52.5 45.9 70.4 61.0 74.4
Mean number of patients at ODC 70.5 88.6 97.9 88.0 72.0 70.4 61.0 74.4
Mean number of DLTs 0.1 0.0 0.0 0.0 0.9 0.0 6.4 0.2
EDC selection percentage 31.5 19.3 16.0 19.1 15.6 24.7 32.3 37.7
Mean number of patients at EDC 31.5 39.8 42.7 35.8 30.1 24.7 32.3 37.7
Dierent prior for plateau parameter 
ODC selection percentage 71.9 54.0 43.3 49.5 42.1 72.4 61.1 78.0
Mean number of patients at ODC 71.9 91.5 96.1 85.8 68.6 72.4 61.1 78.0
Mean number of DLTs 0.3 0.0 0.0 0.0 1.4 0.0 8.3 0.1
EDC selection percentage 32.6 21.7 14.7 18.3 14.7 25.9 32.8 39.5
Mean number of patients at EDC 32.6 42.0 42.6 35.5 29.7 25.9 32.8 39.5
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Table 6. Summarized data from the case study combination clinical trial involving Imatinib with Pacli-
taxel. The number of responses is the addition of stabilities and partial responses.
Cohort Paclitaxel Imatinib No. of evaluable No. of No. of evaluable No. of
no. (mg/m2) (mg) patients for DLT DLTs patients for response responses
1 60 400 3 0 3 1
2 80 400 3 0 3 2
3 80 600 3 0 3 2
4 100 600 3 0 3 1
5 100 800 6 1 4 3
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Figure 1. An illustration of combination zones for the start-up phase.
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